Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (SDS, BC, ASD, MV); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (JJVM, PSJ); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (RAB, CSPL), and Haga Teaching Hospital, the Hague (CJWB) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (AFH); Yale School of Medicine, New Haven, CT (SEI); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (MNK); National Heart Center Singapore and Duke–National University of Singapore, Singapore (CSPL); National University of Cordoba, Cordoba (FM), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires (JT) — both in Argentina; Northwestern University Feinberg School of Medicine, Chicago (SJS); General University Hospital, Charles University, Prague, Czech Republic (JB); General Clinical Research Center and the Division of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-EC); the Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, University of Barcelona, ​​L’Hospitalet de Llobregat, Barcelona (JC-C.); George Emil Palade University of Medicine, Pharmacy, Science, and Technology, Târgu Mureş, Romania (D. Dobreanu); the Department of Cardiology, Medical University Lodz, Lodz, Poland (JD); University of Utah Medical Center, Salt Lake City (JCF); Centro de Estudios Clínicos de Querétaro, Querétaro, Mexico (MAA-G.); the Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia (WAH); the Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (YH); Clínica Vesalio, San Borja, Peru (JWCH); the Department of Cardiovascular Diseases, Cardiac Intensive Care, University Hospitals Leuven, Leuven, Belgium (SPJ); the Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (TK); Kinshukai Hanwa Daini Senboku Hospital, Osaka, Japan (MK); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (BM); Institut de Cardiologie de Montréal, Université de Montréal, Montreal (EO), and the Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto (SV) — both in Canada; the Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil (JFKS); the Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow (SNT); the Minneapolis Veterans Affairs Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis (OV); Cardiovascular Center, Tam Anh Hospital, Tan Tao University, Tan Duc, Vietnam (VNP); and Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (UW, NZ, EB, DL, MP, AML).

Dr. Solomon can be contacted at [email protected] or at the Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115.

Leave a Comment

Your email address will not be published. Required fields are marked *